Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 06, 2018 9:32am
156 Views
Post# 28131125

RE:Time out

RE:Time out
palinc2000 wrote: I think Thera should have a little man to man talk with Taimed.
In less than 24 hours we go from zero sales to so much sales that supply might run into a problem.
There needs to be some coherence and some coordination between the 2 companies with regards to sales numbers.

Some decorum is needed....Taimed should start adapting to North American standards .... if they ever want to list in the Nasdaq ....... 



The problem is the mixed messages, I agree, but you have to remember Taimed did try to prepare its shareholders a while back by saying look beyond the monthly figures. The problem seems to be that Taimed is forced to declare monthly sales but thera, being their only source of sales, doesnt order on a monthly basis so lumpiness is inevitable. To some extent its upto the shareholders to understand that and not panic. If you go back to the contract the companies signed then sales between the two companies are regulated on a quarterly basis, doesnt mean you cant place several orders in a quarter but it also doesnt mean it takes into account Taimeds commitments to declare revenue monthly

If they both decided to be less secretive about say patient numbers and choose to declare that number regularly it would help everybody have a more clear understanding of how things are progressing and add continuity. Just saying :)
Bullboard Posts